Abstract
1 Platelet inhibitory therapy may protect patency in prosthetic arterial grafts.
2 The effect of the thromboxane synthetase inhibitor dazoxiben (UK 37248) on 113Indium-labelled platelet deposition on Dacron arterial grafts was examined in an artificial circulation containing human blood which mimics the haemodynamics of femoropopliteal bypass. The influence of this drug on thromboxane production and platelet reactivity was measured during the experiment. The study was controlled and performed in two parts to assess in vitro and ex vivo drug effect.
3 Both in vitro and ex vivo dazoxiben reduced plasma thromboxane by about 80% and in citrated ex vivo blood increased mean (± s.e. mean) platelet aggregation threshold to collagen from control values of 4.8±1.7 mg/ml to 10.6±3.3 mg/ml (P<0.01). Dazoxiben, however, had no effect on platelet deposition on the arterial grafts.
4 Selective thromboxane inhibition failed to exert an antithrombotic effect in this model.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Best L. C., Holland T. K., Jones P. B., Russell R. G. The interrelationship between thromboxane biosynthesis, aggregation and 5-hydroxytryptamine secretion in human platelets in vitro. Thromb Haemost. 1980 Feb 29;43(1):38–40. [PubMed] [Google Scholar]
- Butler K. D., Maguire E. D., Smith J. R., Turnbull A. A., Wallis R. B., White A. M. Prolongation of rat tail bleeding time caused by oral doses of a thromboxane synthetase inhibitor which have little effect on platelet aggregation. Thromb Haemost. 1982 Feb 26;47(1):46–49. [PubMed] [Google Scholar]
- Christenson J. T., Eklöf B. Sparks mandril, velour Dacron and autogenous saphenous vein grafts in femoropopliteal bypass. Br J Surg. 1979 Jul;66(7):514–517. doi: 10.1002/bjs.1800660720. [DOI] [PubMed] [Google Scholar]
- Clyne C. A., McVeigh J. A., Fox M. J., Jantet G. H., Jamieson C. W. PTFE (Goretex) femoropopliteal reconstruction for limb salvage. Ann R Coll Surg Engl. 1979 Jul;61(4):301–303. [PMC free article] [PubMed] [Google Scholar]
- Dale J., Myhre E., Storstein O., Stormorken H., Efskind L. Prevention of arterial thromboembolism with acetylsalicylic acid. A controlled clinical study in patients with aortic ball valves. Am Heart J. 1977 Jul;94(1):101–111. doi: 10.1016/s0002-8703(77)80351-7. [DOI] [PubMed] [Google Scholar]
- Hamlin G. W., Rajah S. M., Crow M. J., Kester R. C. Evaluation of the thrombogenic potential of three types of arterial graft studied in an artificial circulation. Br J Surg. 1978 Apr;65(4):272–276. doi: 10.1002/bjs.1800650416. [DOI] [PubMed] [Google Scholar]
- McCollum C. N., Crow M. J., Rajah S. M., Kester R. C. Antithrombotic therapy for vascular prosthesis: an experimental model testing platelet inhibitory drugs. Surgery. 1980 Jun;87(6):668–676. [PubMed] [Google Scholar]
- Randall M. J., Parry M. J., Hawkeswood E., Cross P. E., Dickinson R. P. UK-37, 248, a novel, selective thromboxane synthetase inhibitor with platelet anti-aggregatory and anti-thrombotic activity. Thromb Res. 1981 Jul 1;23(1-2):145–162. doi: 10.1016/0049-3848(81)90247-4. [DOI] [PubMed] [Google Scholar]
- Salzman E. W. Influence of antiplatelet drugs on platelet-surface interactions. Adv Exp Med Biol. 1978;102:265–283. doi: 10.1007/978-1-4757-1217-9_18. [DOI] [PubMed] [Google Scholar]
- Sullivan J. M., Harken D. E., Gorlin R. Pharmacologic control of thromboembolic complications of cardiac-valve replacement. N Engl J Med. 1971 Jun 24;284(25):1391–1394. doi: 10.1056/NEJM197106242842501. [DOI] [PubMed] [Google Scholar]
- Vermylen J., Defreyn G., Carreras L. O., Machin S. J., Van Schaeren J., Verstraete M. Thromboxane synthetase inhibition as antithrombotic strategy. Lancet. 1981 May 16;1(8229):1073–1075. doi: 10.1016/s0140-6736(81)92241-8. [DOI] [PubMed] [Google Scholar]
- Yates S. G., 2nd, Nakagawa Y., Berger K., Sauvage L. R. Surface thrombogenicity of arterial prostheses. Surg Gynecol Obstet. 1973 Jan;136(1):12–16. [PubMed] [Google Scholar]